Senseonics Holdings, Inc.

AMEX•SENS

CEO: Dr. Timothy T. Goodnow Ph.D.

セクター: Healthcare

業種: Medical - Devices

上場日: 2015-12-22

Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

連絡先情報

20451 Seneca Meadows Parkway, Germantown, MD, 20876-7005, United States

301-515-7260

www.senseonics.com

時価総額

$264.82M

PER (TTM)

-3.9

3.7

配当利回り

52週高値

$15.74

52週安値

$5.25

52週レンジ

10%

順位53Top 76.1%

2.8

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 2.8 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$14.26M+0.00%

直近4四半期の推移

EPS

-$0.50+0.00%

直近4四半期の推移

フリーCF

-$23.25M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Revenue Grew Substantially Total revenue reached $35.3M, growing $12.8M from $22.5M in 2024, driven by strong US consignment program sales.

Gross Margin Significantly Improved Gross margin expanded sharply to 44.7% in 2025, up from only 2.4% in 2024, aided by product mix and prior year charges.

Net Loss Narrowed Net Loss narrowed by $9.5M to $(69.1M) in 2025, showing operational leverage improvement despite increased SG&A spending.

US Commercial Control Resumed US commercial responsibility fully transitioned back from Ascensia effective January 1, 2026, securing direct market control.

リスク要因

Profitability Remains Uncertain Incurred substantial net losses since inception; profitability remains uncertain for the foreseeable future requiring additional capital.

Increased Operating Expenses SG&A expenses rose $18.3M to $52.5M, driven by US commercialization launch and associated transition costs.

Going Concern Doubt Exists Substantial doubt exists regarding ability to continue as going concern for next twelve months without securing additional liquidity.

Active Patent Litigation Exposure Facing active patent infringement lawsuit; outcome is inherently unpredictable and could result in material adverse financial impact.

見通し

European Revenue Entitlement Expect 100% revenue entitlement from European Territories starting January 1, 2026, following definitive agreement finalization.

Next-Gen Product Pipeline Next-generation Gemini and Freedom systems targeted for commercial launch by Q4 2027 and Q4 2028, respectively.

R&D Spending Optimization R&D expenses decreased $9.5M to $31.6M due to completion of pivotal clinical trials for Eversense 365 system.

Prioritize Payor Coverage Prioritizing payor coverage transition for Eversense 365 to secure favorable reimbursement status across US covered lives.

同業比較

売上高 (TTM)

OMI

$2.76B

-41.0%

TOI

$502.73M

+27.8%

TMCI

$212.69M

+1.6%

粗利益率 (最新四半期)

ACRS

162.0%

+39.1pp

OMI

93.9%

-2.1pp

SMLR

91.5%

+0.1pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
CAPR	$1.41B	-14.5	-0.1%	4.1%
SRDX	$614.51M	-34.8	-15.6%	19.2%
NPCE	$456.52M	-21.1	-105.7%	67.1%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

31.6%

高成長

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月6日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし